We are beyond thrilled to welcome Christine Korbmacher, PhD, MBA, as our new Executive Consultant, CNS at Global Clinical Trials!
Christine, a visionary in CNS innovation, is an accomplished leader with decades of experience in clinical development and operations, specializing in CNS disorders. Her career spans top-tier pharmaceutical, biotech, and CRO organizations, where she has successfully led Phase I–III clinical trials, strategic planning, and regulatory submissions. Notably, she has played a pivotal role in securing multiple NDA approvals across various indications, including multiple sclerosis, migraine, and schizophrenia.
Her therapeutic expertise extends to multiple sclerosis, Alzheimer’s, Parkinson’s disease, numerous rare diseases, and additional CNS conditions. A dynamic leader and team player, Christine has effectively managed global cross-functional teams, CRO partnerships, and clinical development programs, ensuring efficiency and high-quality execution.
With a PhD in Biochemistry, an MBA in Business & Finance, and multiple certifications in GCP, GLP, and GMP, Christine brings strategic insight, innovation, and leadership to our team.
“We are excited to welcome Christine to the GCT team,” said Eugene Selivra, Chief Executive Officer, GCT. “Her expertise and leadership, particularly in CNS, will further strengthen our ability to deliver high-quality services to our clients and support the execution of complex clinical trials of life-changing therapies. We are confident she will be a great fit for GCT.”
Join us in giving Christine a warm welcome as she embarks on this exciting new journey with Global Clinical Trials!